

The direct effects of non-steroidal anti-inflammatory drugs (NSAIDs) on osteoarthritic knee cartilage

Submission date 20/12/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 20/12/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 15/05/2009	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr A C A Marijnissen

Contact details

UMC Utrecht
Rheumatology & Clin. Immunology, F02.127
P.O. Box 85500
Utrecht
Netherlands
3508 GA
+31 (0)30 250 9758
a.c.a.marijnissen@umcutrecht.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Selective COX-2 inhibition is beneficial for matrix turnover: a clinical study

Study objectives

Selective COX-2 inhibition is beneficial for matrix turnover.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from the local medical ethics committee

Study design

Randomised active controlled parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Osteoarthritis

Interventions

Celecoxib: 4 weeks, 2 times per day, 200 mg

Naproxen: 4 weeks, 3 times per day, 250 mg

Indomethacin: 4 weeks, 2 times per day, 50 mg

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Celecoxib, naproxen, indomethacin

Primary outcome measure

Difference in proteoglycan release of osteoarthritic cartilage after treatment

Secondary outcome measures

Proteoglycan E2 levels produced by cartilage

Overall study start date

01/11/2004

Completion date

01/12/2005

Eligibility

Key inclusion criteria

Patients with knee osteoarthritis according to the American College of Rheumatology (ACR) criteria, considered for total knee replacement surgery.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

42

Key exclusion criteria

1. Total knee replacement for other reason than osteoarthritis
2. History of gastro-intestinal bleedings or perforation
3. Increased risk for cardiovascular diseases (cardiovascular diseases in history, patients with untreated hypertension, patients with angina pectoris, and patients on oral anticoagulants)

Date of first enrolment

01/11/2004

Date of final enrolment

01/12/2005

Locations

Countries of recruitment

Netherlands

Study participating centre

UMC Utrecht
Utrecht
Netherlands
3508 GA

Sponsor information

Organisation

University Medical Centre Utrecht (UMCU) (Netherlands)

Sponsor details

PO Box 85500
Utrecht
Netherlands
3508 GA

Sponsor type

University/education

Website

<http://www.umcutrecht.nl/zorg/>

ROR

<https://ror.org/04pp8hn57>

Funder(s)

Funder type

Not defined

Funder Name

Not provided at time of registration

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration